NANOG and neoplasm: The levels of Nanog and β-Catenin were also examined in the tumor tissues collected from the mice treated with the PRC-724 only vs. the reduced tumors in mice with the PRC-724 therapy, demonstrating that the PRC-724 therapy reduced NANOG and β-Catenin/CBP-inducible protein expression in tumors with retarded growth.